AI in biopharma: no longer theoretical

Wednesday, October 14, 2026 | Georgia Room, NYC | Hybrid

The question is no longer if AI can change biopharma. It already has. The first AI-designed drugs are reaching the clinic and record money is flowing. But the payoff is still up in the air.

AI Day returns Oct. 14 for what comes next: What changes for the people building the future of medicine? Endpoints News Senior Biopharma Correspondent Andrew Dunn hosts a day of on-the-record sessions with the researchers, executives and investors deciding it.

Join us in New York, where the conversation keeps going over an open bar and heavy hors d'oeuvres. Or tune in to the virtual program.

SELECT YOUR PASS

Save $100 with code AIDAY100. Limited in-person spots available.

Be in the room with:

Nathan Frey, head of drug discovery and development research at Anthropic
Sydney Klein, chief information security officer at Bristol Myers Squibb
Subbu Iyer, head of AI and data at Takeda
Najat Khan, CEO and president of Recursion (in-person exclusive)
Zavain Dar, founder and managing partner at Dimension (in-person exclusive)
and more

Nathan Frey, Anthropic

After virtual morning sessions with:

David Baker, director of the Institute for Protein Design at the University of Washington
Travis Zack, chief medical officer at OpenEvidence
Melissa J. Moore, co-founder of Kerna Labs and Waterfall Scientific
and more

SELECT YOUR PASS

Save $100 with code AIDAY100. Limited in-person spots available.